Consolidation among mid-sized specialty Pharma companies continues to shrink this pool of companies. Now there are just a handful of players who have not been merged or bought, and the likelihood is that the trend will continue. This is particularly true for those companies like Activis whose strategy is growth by acquisition not by slow organic growth. This should be interesting reading in the coming two years.
http://lnkd.in/M_kVHJ
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022